WO2009011889A4 - Compounds and methods for treatment of sickle cell disease or complications associated therewith - Google Patents
Compounds and methods for treatment of sickle cell disease or complications associated therewith Download PDFInfo
- Publication number
- WO2009011889A4 WO2009011889A4 PCT/US2008/008745 US2008008745W WO2009011889A4 WO 2009011889 A4 WO2009011889 A4 WO 2009011889A4 US 2008008745 W US2008008745 W US 2008008745W WO 2009011889 A4 WO2009011889 A4 WO 2009011889A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- compound
- associated therewith
- sickle cell
- cell disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 11
- 208000007056 sickle cell anemia Diseases 0.000 title claims abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Abstract
Compounds, compositions and methods are provided for treatment of sickle cell disease or a complication associated therewith, or graft versus host disease, in an individual. More specifically, the use of particular glycomimetics for the treatment is described.
Claims
AMENDED CLAIMS received by the International Bureau on 11 March 2009 (11.03.09)
10. Use of a compound for the preparation of a composition for the treatment of sickle cell disease or a complication associated therewith, the compound with the formula:
L = linker group; and n = 0-1.
11. Use of a compound for the preparation of a medicament for the treatment of sickle cell disease or a complication associated therewith, the compound with the formula:
L = linker group; and n = 0-1.
12. The use according to claim 10 or claim 11 wherein in the compound n=0.
AMENDED SHEET (ARTICLE 19)
13. The use according to claim 10 or claim 11 wherein in the compound n=1 and L is
where the N of L is attached to terminal C of C(=O) of the compound.
14. The use according to claim 10 or claim 11 wherein in the compound n=1 and L is
AMENDED SHEET (ARTICLE 19)
19
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08794556A EP2173351A2 (en) | 2007-07-18 | 2008-07-16 | Compounds and methods for treatment of sickle cell disease or complications associated therewith |
CA2693590A CA2693590A1 (en) | 2007-07-18 | 2008-07-16 | Compounds and methods for treatment of sickle cell disease or complications associated therewith |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95998407P | 2007-07-18 | 2007-07-18 | |
US60/959,984 | 2007-07-18 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2009011889A2 WO2009011889A2 (en) | 2009-01-22 |
WO2009011889A3 WO2009011889A3 (en) | 2009-03-05 |
WO2009011889A4 true WO2009011889A4 (en) | 2009-04-23 |
Family
ID=40044164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/008745 WO2009011889A2 (en) | 2007-07-18 | 2008-07-16 | Compounds and methods for treatment of sickle cell disease or complications associated therewith |
Country Status (5)
Country | Link |
---|---|
US (2) | US8039442B2 (en) |
EP (1) | EP2173351A2 (en) |
CA (1) | CA2693590A1 (en) |
WO (1) | WO2009011889A2 (en) |
ZA (1) | ZA201000316B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8039442B2 (en) | 2007-07-18 | 2011-10-18 | Glycomimetics, Inc. | Compounds and methods for treatment of sickle cell disease or complications associated therewith |
WO2009126556A1 (en) | 2008-04-08 | 2009-10-15 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
ES2426784T3 (en) * | 2008-06-13 | 2013-10-25 | Glycomimetics, Inc. | Treatment of blood cancers using selected glyomimetic compounds |
US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
WO2012047918A1 (en) * | 2010-10-04 | 2012-04-12 | Glycomimetics, Inc. | Anti-epileptogenic agents |
WO2013096926A1 (en) | 2011-12-22 | 2013-06-27 | Glycomimetics, Inc. | E-selectin antagonist compounds, compositions, and methods of use |
ES2668045T3 (en) | 2012-12-07 | 2018-05-16 | Glycomimetics, Inc. | Compounds, compositions and methods that use E-selectin antagonists for the mobilization of hematopoietic cells |
SI3227310T1 (en) | 2014-12-03 | 2019-11-29 | Glycomimetics Inc | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
WO2018031445A1 (en) | 2016-08-08 | 2018-02-15 | Glycomimetics, Inc. | Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4 |
CA3037850A1 (en) | 2016-10-07 | 2018-04-12 | Glycomimetics, Inc. | Highly potent multimeric e-selectin antagonists |
CA3054605A1 (en) | 2017-03-15 | 2018-09-20 | Glycomimetics, Inc. | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
WO2019108750A1 (en) | 2017-11-30 | 2019-06-06 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
EP3732186A1 (en) | 2017-12-29 | 2020-11-04 | GlycoMimetics, Inc. | Heterobifunctional inhibitors of e-selectin and galectin-3 |
AU2019230013A1 (en) | 2018-03-05 | 2020-09-10 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
EP3886984A1 (en) | 2018-11-29 | 2021-10-06 | Pfizer Inc. | Pyrazoles as modulators of hemoglobin |
US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4471057A (en) * | 1981-06-30 | 1984-09-11 | The Wistar Institute | Detection of colorectal carcinoma |
DK17885D0 (en) * | 1985-01-14 | 1985-01-14 | Karlsson Karl Anders | ANTIVIRAL AGENT |
US4876199A (en) * | 1985-04-04 | 1989-10-24 | Fred Hutchinson Cancer Research Center | Hybridomas producing monoclonal antibodies to mono-, di-, and trifucosylated type 2 chain |
US4851511A (en) * | 1986-01-30 | 1989-07-25 | Fred Hutchinson Cancer Research Center | Monoclonal antibody that specifically binds to disialosyl Lea |
US4925796A (en) * | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
DE3787403D1 (en) * | 1986-05-09 | 1993-10-21 | Pulverer Gerhard | Use of specific monosaccharides for the manufacture of a medicament for the prevention of metastases of malignant tumors. |
US5538724A (en) * | 1987-08-11 | 1996-07-23 | The Board Of Trustees For The Leland Stanford Junior Univ. | Method of control leukocyte extravasation |
US5464778A (en) | 1989-03-08 | 1995-11-07 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for P-selectin and methods of use thereof |
US6033665A (en) * | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
US6001988A (en) | 1990-06-11 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands to lectins |
US6280932B1 (en) * | 1990-06-11 | 2001-08-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands to lectins |
US5576305A (en) | 1990-06-15 | 1996-11-19 | Cytel Corporation | Intercellular adhesion mediators |
US5753631A (en) * | 1990-06-15 | 1998-05-19 | Cytel Corporation | Intercellular adhesion mediators |
US6391857B1 (en) * | 1990-06-18 | 2002-05-21 | Stanford University | Methods and compositions for endothelial binding |
US6387884B1 (en) * | 1990-06-18 | 2002-05-14 | Stanford University | Leukocyte homing modulation |
US5211937A (en) * | 1990-07-30 | 1993-05-18 | Glycomed Incorporated | Method of determining a site of inflammation utilizing elam-1 ligands |
US5648344A (en) * | 1990-07-30 | 1997-07-15 | Glycomed Incorporated | Methods of treating inflammation using selection binding compounds |
US5143712A (en) * | 1990-07-30 | 1992-09-01 | Glycomed Incorporated | Method of determining a site of inflammation utilizing elam-1 ligands |
US5789573A (en) * | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
WO1992009293A1 (en) * | 1990-11-23 | 1992-06-11 | The General Hospital Corporation | Inhibition of cell adhesion protein-carbohydrate interactions |
US5151360A (en) * | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
US6124267A (en) * | 1991-02-05 | 2000-09-26 | Southpac Trust Internationals, Inc. | O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1 |
US6309639B1 (en) * | 1991-02-05 | 2001-10-30 | The Board Of Regents Of The University Of Oklahoma | Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand |
US6121233A (en) * | 1991-04-19 | 2000-09-19 | John L. Magnani | Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules |
US5318890A (en) * | 1991-05-06 | 1994-06-07 | The Regents Of The University Of California | Assays for inhibitors of leukocyte adhesion |
ES2201049T3 (en) * | 1991-05-06 | 2004-03-16 | Genentech, Inc. | A BINDING OF SELECTINE. |
US5646123A (en) * | 1991-06-10 | 1997-07-08 | Alberta Research Council | Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen |
US5352670A (en) * | 1991-06-10 | 1994-10-04 | Alberta Research Council | Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides |
US5580858A (en) | 1991-06-10 | 1996-12-03 | Alberta Research Council | Immunosuppressive and tolerogenic modified Lewisx compounds |
CA2118695A1 (en) * | 1991-09-10 | 1993-03-18 | George A. Heavner | Peptide inhibitors of inflammation mediated by selectins |
US5268364A (en) | 1991-12-12 | 1993-12-07 | The Biomembrane Institute | Method for inhibiting selectin-dependent adhesion of leukocytes and platelets by O-glycosylation modification |
WO1994004568A1 (en) * | 1991-12-18 | 1994-03-03 | Centocor, Inc. | Peptide inhibitors of inflammation mediated by selectins |
US5591835A (en) * | 1992-06-29 | 1997-01-07 | Glycomed Incorporated | Substituted lactose derivatives |
CA2100412A1 (en) * | 1992-07-15 | 1994-01-16 | Yutaka Yamada | Glycolipid derivatives |
JPH08503694A (en) * | 1992-09-08 | 1996-04-23 | セントコー・インコーポレーテッド | Peptide-based cell adhesion inhibitor |
US5519008A (en) * | 1992-09-10 | 1996-05-21 | Glycomed Incorporated | Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin) |
AU4859793A (en) | 1992-09-11 | 1994-04-12 | Regents Of The University Of California, The | Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation |
US5695752A (en) | 1992-09-11 | 1997-12-09 | The Regents Of The University Of California | Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor |
US5843707A (en) * | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
US6277975B1 (en) * | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
EP0601417A3 (en) | 1992-12-11 | 1998-07-01 | Hoechst Aktiengesellschaft | Physiologically compatible and degradable polymer-based carbohydrate receptor blockers, a method for their preparation and their use |
WO1994014836A1 (en) * | 1992-12-18 | 1994-07-07 | Centocor, Inc. | Peptide inhibitors of selectin binding |
AU678429B2 (en) * | 1992-12-29 | 1997-05-29 | Genentech Inc. | Treatment of inflammatory bowel disease with IFN-gamma inhibitors |
US5412123A (en) * | 1993-02-08 | 1995-05-02 | Glycomed Incorporated | Anthraquinone and anthracene derivatives as inhibitors of the cell-adhesion molecules of the immune system |
EP0687684A4 (en) * | 1993-03-04 | 1998-03-04 | Kanto Ishi Pharma Co Ltd | Lewis-associated compound, process for producing the same, and anti-inflammatory |
US5527890A (en) * | 1993-04-16 | 1996-06-18 | Glycomed Incorporated | Derivatives of triterpenoid acids and uses thereof |
US5854218A (en) | 1993-05-14 | 1998-12-29 | Cytel Corporation | Sialyl Lex analogues as inhibitors of cellular adhesion |
NZ266972A (en) * | 1993-05-14 | 1997-08-22 | Cytel Corp | Sialyl lewis analogues, compounds, preparation, and pharmaceutical compositions |
US5811404A (en) * | 1993-05-14 | 1998-09-22 | Cytel Corporation | Sialyl Lex analogues as inhibitors of cellular adhesion |
US5527785A (en) * | 1993-05-14 | 1996-06-18 | The Regents Of The University Of California | Selectin receptor modulating compositions |
WO1994026786A1 (en) * | 1993-05-17 | 1994-11-24 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5976540A (en) | 1993-05-17 | 1999-11-02 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5646248A (en) * | 1993-06-08 | 1997-07-08 | La Jolla Cancer Research Foundation | E-selection binding soluble lamp-1 polypeptide |
US5658880A (en) * | 1993-06-16 | 1997-08-19 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
US5789385A (en) * | 1993-06-16 | 1998-08-04 | Glycomed Incorporated | Sialyl Lewisx mimetics containing phenyl backbones |
US5837689A (en) | 1993-06-16 | 1998-11-17 | Glycomed Incorporated | Sialyl lewis-x mimetics containing naphthyl backbones |
US5750508A (en) * | 1993-06-16 | 1998-05-12 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
US5679321A (en) * | 1993-06-17 | 1997-10-21 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
US5559103A (en) * | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
US5508387A (en) * | 1993-08-04 | 1996-04-16 | Glycomed Incorporated | Selectin binding glycopeptides |
WO1995005830A1 (en) * | 1993-08-20 | 1995-03-02 | The Regents Of The University Of California | Polyanion anti-inflammatory agents |
US5464815A (en) | 1993-09-08 | 1995-11-07 | Genentech, Inc. | Inhibition of heparin-binding |
WO1995010296A1 (en) * | 1993-10-12 | 1995-04-20 | Glycomed Incorporated | A library of glyco-peptides useful for identification of cell adhesion inhibitors |
US5783693A (en) | 1993-11-19 | 1998-07-21 | The Regents Of The University Of California | Methods for synthesizing sulfated disaccharide inhibitors of selectins |
WO1995014787A1 (en) * | 1993-11-22 | 1995-06-01 | Centocor, Inc. | Peptide inhibitors of selecting binding |
US5663151A (en) * | 1994-03-04 | 1997-09-02 | Bristol-Myers Squibb Company | Sulfated α-glycolipid derivatives as cell adhesion inhibitors |
EP0671409A3 (en) | 1994-03-11 | 1996-06-12 | Hoechst Ag | Malonic acid derivatives having anti-adhesive properties. |
DE4408248A1 (en) * | 1994-03-11 | 1995-09-14 | Hoechst Ag | Physiologically acceptable and physiologically degradable carbohydrate mimetics, process for their preparation and their use |
US5444050A (en) * | 1994-04-29 | 1995-08-22 | Texas Biotechnology Corporation | Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa |
HUT77345A (en) * | 1994-04-29 | 1998-03-30 | Texas Biotechnology Corporation | Mannopyranosyloxy biphenyl derivatives capable of inhibiting the binding of e-selectin,p-selectin or l-selectin to sialyl-lewis x or sialyl-lewis a and pharmaceutical compositions containing them |
US5486536A (en) * | 1994-08-15 | 1996-01-23 | The Regents Of The University Of Michigan | Sulfatides as anti-inflammatory compounds |
JPH0899989A (en) | 1994-09-30 | 1996-04-16 | Akira Hasegawa | New glycolipid derivative and intermediate for its production |
DE4436164A1 (en) * | 1994-10-10 | 1996-04-11 | Hoechst Ag | New conjugates of tetra:carbohydrate and amide-linked peptide or dye etc. |
US5686426A (en) | 1994-11-17 | 1997-11-11 | Bristol-Myers Squibb Company | Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors |
US6492332B1 (en) | 1995-12-12 | 2002-12-10 | Omeros Corporation | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation |
US5639734A (en) * | 1994-12-20 | 1997-06-17 | Esko; Jeffrey D. | Disaccharide inflammation inhibitors and uses thereof |
US20020040008A1 (en) * | 1995-01-24 | 2002-04-04 | Wagner Denisa D. | Method for treating and preventing atherosclerosis |
US5736533A (en) | 1995-06-07 | 1998-04-07 | Neose Technologies, Inc. | Bacterial inhibition with an oligosaccharide compound |
US5876715A (en) * | 1995-08-17 | 1999-03-02 | The Biomembrane Institute | Antibodies that bind novel carbohydrate ligands (myelorollins) that cause E-selectin dependent cell rolling, and uses thereof |
DE19532902A1 (en) * | 1995-09-06 | 1997-03-13 | Hoechst Ag | Novel glycomimetics as selectin antagonists and anti-inflammatory drugs made from them |
DE19537334A1 (en) * | 1995-10-09 | 1997-04-10 | Hoechst Ag | New piperidine carboxylic acid and pyrrolidine carboxylic acid derivs. |
US5919769A (en) * | 1995-10-26 | 1999-07-06 | Kanebo, Ltd | Fucose derivatives, drugs containing the same as active ingredient, and intermediates for producing the same |
US5747463A (en) * | 1995-11-13 | 1998-05-05 | Bristol-Myers Squibb Company | Malonate derivatives of glycolipids as cell adhesion inhibitors |
DE19602355A1 (en) * | 1996-01-24 | 1997-07-31 | Hoechst Ag | Multiple fucosylated dicarboxylic acids with anti-adhesive properties |
WO1997028173A1 (en) * | 1996-01-30 | 1997-08-07 | Novartis Ag | SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES |
US6187754B1 (en) * | 1996-01-30 | 2001-02-13 | Glycotech Corp. | Sialyl-Lewisa and sialyl-Lewisx epitode analogues |
US5710023A (en) * | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
WO1997031625A1 (en) | 1996-03-01 | 1997-09-04 | The Regents Of The University Of California | Inhibition of selectin binding |
US5654412A (en) * | 1996-05-29 | 1997-08-05 | Glycomed Incorporated | Processes for the synthesis of sialyl Lewisx compounds |
CA2197058A1 (en) | 1996-06-05 | 1997-12-06 | Avery B. Nathens | Anti-inflammatory agent |
US5919768A (en) * | 1996-06-26 | 1999-07-06 | Texas Biotechnology Corporation | Di- and trivalent small molecule selectin inhibitors |
US5830871A (en) | 1996-10-28 | 1998-11-03 | The Scripps Research Institute | Inhibitors of E-, P- and L-selectin binding |
GB9618520D0 (en) * | 1996-09-05 | 1996-10-16 | Chiroscience Ltd | Compounds and their therapeutic use |
US6110897A (en) * | 1996-10-10 | 2000-08-29 | Glycorex Ab | Antiinflammatory cell adhesion inhibitors |
US6235309B1 (en) * | 1997-02-28 | 2001-05-22 | The Regents Of The University Of California | Inhibition of cell-cell binding by lipid assemblies |
US6120751A (en) * | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
SE9701127D0 (en) * | 1997-03-26 | 1997-03-26 | Karolinska Innovations Ab | Antigenic fusion protein carrying GALal, 3GAL epitopes |
US5916910A (en) * | 1997-06-04 | 1999-06-29 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
US6193973B1 (en) * | 1997-08-22 | 2001-02-27 | B. David Tuttle | Dietary supplement for boosting energy and increasing muscular strength |
US5948628A (en) * | 1997-09-05 | 1999-09-07 | The Board Of Regents Of The University Of Oklahoma | Methods of screening for compounds which mimic galectin-1 |
WO1999043353A2 (en) | 1998-02-26 | 1999-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination anti-selectin and immunosuppressant therapy |
US6265192B1 (en) | 1998-03-20 | 2001-07-24 | The Regents Of The University Of California | Glycosly sulfortransferase-3 |
US6365365B1 (en) | 1998-03-20 | 2002-04-02 | The Regents Of The University Of California | Method of determining whether an agent modulates glycosyl sulfotransferase-3 |
US6037333A (en) * | 1998-05-07 | 2000-03-14 | Trustees Of Tufts College | Microbe-inhibiting compositions |
DE69934890D1 (en) * | 1998-06-16 | 2007-03-08 | Univ Oklahoma | GLYCOSULFOPEPTIDES AND PROCESS FOR THEIR PRODUCTION AND THEIR USE |
US6503885B1 (en) * | 1998-09-21 | 2003-01-07 | Otsuka Pharmaceutical Co., Ltd. | Carboxymethylgalactose derivatives |
RU2227752C2 (en) | 1998-11-12 | 2004-04-27 | Новолитикс Инк. | Method for overlapping circulation and compositions for their realization |
CA2408883A1 (en) * | 2000-05-19 | 2001-11-29 | The Center For Blood Research, Inc. | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
US20020132220A1 (en) * | 2000-12-27 | 2002-09-19 | Berens Kurt L. | Use of selectin antagonists in organ preservation solutions |
US20030198639A1 (en) * | 2002-04-16 | 2003-10-23 | Frenette Paul S. | Methods of treating sickle cell disease |
US7087212B2 (en) * | 2001-08-17 | 2006-08-08 | Mallinckrodt, Inc | Multicomponent assemblies having enhanced binding properties for diagnosis and therapy |
WO2003088980A1 (en) | 2002-04-18 | 2003-10-30 | Embury Stephen H | Method and composition for preventing pain in sickle cell patients |
AU2003249641B2 (en) | 2002-05-16 | 2009-08-20 | Glycomimetics, Inc. | Compounds and methods for inhibiting selectin-mediated function |
US20040219158A1 (en) | 2003-05-02 | 2004-11-04 | Glycomimetics, Inc. | Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria |
WO2005054264A2 (en) * | 2003-11-19 | 2005-06-16 | Glycomimetics, Inc. | Glycomimetic antagonists for both e- and p-selectins |
WO2006105019A1 (en) | 2005-03-25 | 2006-10-05 | Wisconsin Alumni Research Foundation | Compounds and methods for treating seizure disorders |
US20060287253A1 (en) | 2005-06-17 | 2006-12-21 | Kriegler Steven M | Compounds and methods for treating seizure disorders |
US7728117B2 (en) * | 2005-09-02 | 2010-06-01 | Glycomimetics, Inc. | Heterobifunctional pan-selectin inhibitors |
EP2117561A1 (en) * | 2007-02-09 | 2009-11-18 | GlycoMimetics, Inc. | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines |
US8039442B2 (en) | 2007-07-18 | 2011-10-18 | Glycomimetics, Inc. | Compounds and methods for treatment of sickle cell disease or complications associated therewith |
-
2008
- 2008-07-11 US US12/218,213 patent/US8039442B2/en active Active
- 2008-07-16 WO PCT/US2008/008745 patent/WO2009011889A2/en active Application Filing
- 2008-07-16 EP EP08794556A patent/EP2173351A2/en not_active Withdrawn
- 2008-07-16 CA CA2693590A patent/CA2693590A1/en not_active Abandoned
-
2010
- 2010-01-15 ZA ZA201000316A patent/ZA201000316B/en unknown
-
2011
- 2011-09-23 US US13/243,873 patent/US8361975B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ZA201000316B (en) | 2010-10-27 |
WO2009011889A2 (en) | 2009-01-22 |
US8361975B2 (en) | 2013-01-29 |
CA2693590A1 (en) | 2009-01-22 |
WO2009011889A3 (en) | 2009-03-05 |
US20120015898A1 (en) | 2012-01-19 |
EP2173351A2 (en) | 2010-04-14 |
US20090023679A1 (en) | 2009-01-22 |
US8039442B2 (en) | 2011-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009011889A4 (en) | Compounds and methods for treatment of sickle cell disease or complications associated therewith | |
WO2006095159A8 (en) | (imidazolo-5-yl)-2-anilo-pyrimidines as agents for the inhibition of cell proliferation | |
PH12019500959A1 (en) | Combinations of sglt 2 inhibitors and antidiabetic agents | |
WO2008003766A3 (en) | 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments | |
WO2008137758A3 (en) | Amino acid lipids and uses thereof | |
WO2009003998A3 (en) | Antiproliferative compounds based on 5-membered heterocycles | |
SG155961A1 (en) | Pyrazoles as 11-beta-hsd-1 | |
WO2009010416A3 (en) | Inhibitors of 11b-hydroxysteroid dehydrogenase | |
WO2009003999A3 (en) | Chemical compounds | |
DE602006009095D1 (en) | Diacylglycerol-acyltransferase-hemmer | |
WO2006099941A8 (en) | Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments | |
GEP20135803B (en) | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives | |
WO2006105888A3 (en) | Synergistic fungicidal active substance combinations | |
WO2007061360A3 (en) | Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides | |
WO2008049758A3 (en) | Disperse dyes, their preparation and their use | |
WO2006077025A3 (en) | Morpholines as 5ht2c agonists | |
WO2009062112A3 (en) | Use of tam receptor inhibitors as antimicrobials | |
WO2007082808A3 (en) | Thiazoles as 11 beta-hsd1 inhibitors | |
WO2010093849A3 (en) | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | |
WO2008020227A3 (en) | Antibacterial pyrrolecarboxamides | |
MX2010001733A (en) | Imidazopyrazine compounds. | |
WO2007014619A8 (en) | Novelimidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same | |
WO2008020229A3 (en) | Antibacterial pyrrolecarboxamides | |
WO2008010238A3 (en) | Antidiabetic azabicyclo [3. 1. 0] hexan compounds | |
WO2009000832A3 (en) | Chemical compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08794556 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2693590 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 678/DELNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008794556 Country of ref document: EP |